Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Inclusion Criteria:

• Patients with plasma cell myeloma treated with any number of prior lines of therapy,who at the time of study enrollment have had sustained MRD-negativity at a giventimepoint and a subsequent time point with an interval of 3 or more years while oncontinuous maintenance therapy. MRD-negativity is defined per the InternationalMyeloma Working Group Consensus Panel.

• MRD positivity will be defined by detection of 1 or more neoplastic plasma cells in 10^5 nucleated cells by flow cytometry as per IMWG criteria (i.e., sensitivity of 10-5)

• Age >/= 18 years with ECOG performance status </= 2

• Patients must be able to understand and be willing to sign a voluntary informedconsent form and agree to compliance with the protocol schedule; with the knowledgethat they may withdraw consent at any time without impact on future medical care

Exclusion Criteria:

• Patients found to be MRD-positive at time of screening

• Patients with plasma cell leukemia or other disorder of plasma cell neoplasm

• Patient who are receiving other therapy with the intent of treating myeloma with theexception of bisphosphonates

• Patients being treated for another, potentially life-limiting malignancy with 3-yearlead-in to study enrollment, with the exception of non-melanoma skin cancer or insitu malignancy or malignancies that have received definitive curative therapy

• Prior organ transplant or condition requiring immunosuppressive therapy

• Prior allogeneic hematopoietic cell transplant

• Patients with any other ongoing, concomitant, comorbid illness including but notlimited to uncontrolled diabetes, NYHA class III or IV heart failure, uncontrolledcoronary artery disease/arrhythmia, psychiatric or social disorder that wouldcompromise compliance with the study schema